Koshinski Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $748K | Sell |
1,505
-103
| -6% | -$45.6K | 0.04% | 361 |
|
|
2026
Q1 | $718K | Buy |
1,608
+152
| +10% | +$70.9K | 0.04% | 342 |
|
|
2025
Q4 | $660K | Buy |
1,456
+117
| +9% | +$50.4K | 0.04% | 354 |
|
|
2025
Q3 | $524K | Buy |
1,339
+39
| +3% | +$16.3K | 0.04% | 407 |
|
|
2025
Q2 | $579K | Buy |
1,300
+2
| +0.2% | +$922 | 0.04% | 369 |
|
|
2025
Q1 | $629K | Sell |
1,298
-59
| -4% | -$27.5K | 0.05% | 331 |
|
|
2024
Q4 | $546K | Buy |
1,357
+45
| +3% | +$20.9K | 0.05% | 346 |
|
|
2024
Q3 | $610K | Sell |
1,312
-14
| -1% | -$6.72K | 0.05% | 324 |
|
|
2024
Q2 | $644K | Buy |
+1,326
| New | +$576K | 0.06% | 291 |
|
|
2024
Q1 | – | Sell |
-500
| Closed | -$203K | – | 642 |
|
|
2023
Q4 | $203K | Sell |
500
-1,004
| -67% | -$371K | 0.03% | 472 |
|
|
2023
Q3 | $523K | Sell |
1,504
-56
| -4% | -$19.6K | 0.06% | 310 |
|
|
2023
Q2 | $549K | Buy |
1,560
+71
| +5% | +$23.9K | 0.06% | 322 |
|
|
2023
Q1 | $469K | Buy |
1,489
+10
| +0.7% | +$3K | 0.05% | 345 |
|
|
2022
Q4 | $427K | Buy |
1,479
+14
| +1% | +$4.27K | 0.04% | 393 |
|
|
2022
Q3 | $424K | Sell |
1,465
-122
| -8% | -$35.1K | 0.05% | 354 |
|
|
2022
Q2 | $447K | Sell |
1,587
-220
| -12% | -$58.9K | 0.04% | 389 |
|
|
2022
Q1 | $472K | Sell |
1,807
-404
| -18% | -$95.9K | 0.04% | 407 |
|
|
2021
Q4 | $486K | Buy |
2,211
+201
| +10% | +$39.1K | 0.04% | 404 |
|
|
2021
Q3 | $365K | Sell |
2,010
-449
| -18% | -$87.7K | 0.03% | 459 |
|
|
2021
Q2 | $496K | Sell |
2,459
-644
| -21% | -$135K | 0.06% | 330 |
|
|
2021
Q1 | $667K | Buy |
3,103
+675
| +28% | +$148K | 0.07% | 306 |
|
|
2020
Q4 | $574K | Buy |
2,428
+341
| +16% | +$78.2K | 0.07% | 289 |
|
|
2020
Q3 | $573K | Sell |
2,087
-241
| -10% | -$66.5K | 0.08% | 264 |
|
|
2020
Q2 | $676K | Buy |
2,328
+879
| +61% | +$238K | 0.11% | 224 |
|
|
2020
Q1 | $345K | Buy |
1,449
+47
| +3% | +$10.8K | 0.07% | 318 |
|
|
2019
Q4 | $307K | Buy |
+1,402
| New | +$284K | 0.05% | 400 |
|
|
2019
Q1 | – | Sell |
-2,887
| Closed | -$478K | – | 464 |
|
|
2018
Q4 | $478K | Sell |
2,887
-1,095
| -27% | -$190K | 0.12% | 217 |
|
|
2018
Q3 | $767K | Sell |
3,982
-4,050
| -50% | -$721K | 0.11% | 247 |
|
|
2018
Q2 | $1.36M | Sell |
8,032
-40
| -0.5% | -$6.2K | 0.42% | 76 |
|
|
2018
Q1 | $1.32M | Buy |
+8,072
| New | +$1.32M | 0.41% | 80 |
|
|
2017
Q3 | – | Sell |
-1,709
| Closed | -$220K | – | 370 |
|
|
2017
Q2 | $220K | Buy |
+1,709
| New | +$206K | 0.08% | 332 |
|
Other funds holding VRTX
Koshinski Asset Management's VRTX Position: Q2 2026 in Review
Koshinski Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 6.4% in Q2 2026, selling an estimated $45.6K and leaving 1,505 shares worth $748K. The position accounts for 0.04% of the portfolio, ranked #361.
Koshinski Asset Management first reported a position in VRTX in Q2 2017 and has held it in 31 quarters since. The position peaked at $1.36M in Q2 2018. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Koshinski Asset Management held 1,505 shares of Vertex Pharmaceuticals worth $748K as of Q2 2026.
- Koshinski Asset Management sold 103 Vertex Pharmaceuticals shares in Q2 2026, an estimated $45.6K.
- Vertex Pharmaceuticals made up 0.04% of Koshinski Asset Management's portfolio in Q2 2026, its #361 holding.
- Koshinski Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 31 quarters since.
- Koshinski Asset Management's Vertex Pharmaceuticals position peaked at $1.36M in Q2 2018.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Koshinski Asset Management's 13F filing for Q2 2026, filed 27 Jul 2026.